Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden.
Absenteeism
Adolescent
Adult
Colitis, Ulcerative
/ economics
Crohn Disease
/ economics
Female
Health Care Costs
/ statistics & numerical data
Health Resources
/ economics
Hospitalization
/ economics
Humans
Incidence
Male
Middle Aged
Prevalence
Sick Leave
/ economics
Sweden
/ epidemiology
Tumor Necrosis Factor-alpha
/ therapeutic use
Work
/ economics
Young Adult
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
28
11
2019
revised:
08
01
2020
accepted:
25
05
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
2
12
2020
Statut:
ppublish
Résumé
There are limited data on population-wide assessment of cost in Crohn's disease (CD) and ulcerative colitis (UC). To estimate the societal cost of actively treated CD and UC in Sweden. We identified 10 117 prevalent CD and 19 762 prevalent UC patients, aged ≥18 years on 1 January 2014 and 4028 adult incident CD cases and 8659 adult incident UC cases (2010-2013) from Swedish Patient Register. Each case was matched to five population comparators. Healthcare costs were calculated from medications, outpatient visits, hospitalisations and surgery. Cost of productivity losses was derived from disability pension and sick leave. The mean annual societal costs per working-age patient (18-64 years) with CD and UC were $22 813 (vs $7533 per comparator) and $14 136 (vs $7351 per comparator), respectively. In patients aged ≥65 years, the mean annual costs of CD and UC were $9726 and $8072 vs $3875 and $4016 per comparator, respectively. The majority of cost for both CD (56%) and UC (59%) patients originated from productivity losses. Higher societal cost of working-age CD patients as compared to UC patients was related to greater utilisation of anti-TNF (22.2% vs 7.4%) and increased annual disability pension (44 days vs 25 days). Among incident CD and UC patients, the mean total cost over the first year per patient was over three times higher than comparators. In Sweden, the societal cost of incident and prevalent CD and UC patients was consistently two to three times higher than the general population.
Sections du résumé
BACKGROUND
There are limited data on population-wide assessment of cost in Crohn's disease (CD) and ulcerative colitis (UC).
AIM
To estimate the societal cost of actively treated CD and UC in Sweden.
METHODS
We identified 10 117 prevalent CD and 19 762 prevalent UC patients, aged ≥18 years on 1 January 2014 and 4028 adult incident CD cases and 8659 adult incident UC cases (2010-2013) from Swedish Patient Register. Each case was matched to five population comparators. Healthcare costs were calculated from medications, outpatient visits, hospitalisations and surgery. Cost of productivity losses was derived from disability pension and sick leave.
RESULTS
The mean annual societal costs per working-age patient (18-64 years) with CD and UC were $22 813 (vs $7533 per comparator) and $14 136 (vs $7351 per comparator), respectively. In patients aged ≥65 years, the mean annual costs of CD and UC were $9726 and $8072 vs $3875 and $4016 per comparator, respectively. The majority of cost for both CD (56%) and UC (59%) patients originated from productivity losses. Higher societal cost of working-age CD patients as compared to UC patients was related to greater utilisation of anti-TNF (22.2% vs 7.4%) and increased annual disability pension (44 days vs 25 days). Among incident CD and UC patients, the mean total cost over the first year per patient was over three times higher than comparators.
CONCLUSION
In Sweden, the societal cost of incident and prevalent CD and UC patients was consistently two to three times higher than the general population.
Identifiants
pubmed: 32902894
doi: 10.1111/apt.15889
pmc: PMC7490827
mid: NIHMS1614784
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
655-668Subventions
Organisme : NIDDK NIH HHS
ID : R03 DK113337
Pays : United States
Investigateurs
Malin Olsson
(M)
Henrik Hjortswang
(H)
Jonas Bengtsson
(J)
Hans Strid
(H)
Marie Andersson
(M)
Susanna Jäghult
(S)
Michael Eberhardsson
(M)
Caroline Nordenvall
(C)
Jan Björk
(J)
Ulrika Fagerberg
(U)
Martin Rejler
(M)
Olof Grip
(O)
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Am J Gastroenterol. 2003 May;98(5):1064-72
pubmed: 12809829
Health Policy. 1996 Jun;36(3):231-44
pubmed: 10158268
Scand J Gastroenterol. 2017 Feb;52(2):216-221
pubmed: 27797278
Gastroenterol Hepatol. 2016 Jan;39(1):9-19
pubmed: 26211705
PLoS One. 2016 Apr 21;11(4):e0142481
pubmed: 27099937
Inflamm Bowel Dis. 2017 Aug;23(8):1262-1271
pubmed: 28691933
Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):253-66
pubmed: 25656310
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Dig Dis Sci. 2017 Sep;62(9):2318-2326
pubmed: 28766243
Aliment Pharmacol Ther. 2018 Dec;48(11-12):1174-1185
pubmed: 30378141
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Gastroenterology. 2008 Dec;135(6):1907-13
pubmed: 18854185
Ann Rheum Dis. 2015 Jun;74(6):1094-101
pubmed: 24737786
Inflamm Bowel Dis. 2019 Nov 14;25(12):1881-1885
pubmed: 30934057
N Engl J Med. 2010 Apr 15;362(15):1383-95
pubmed: 20393175
Eur J Epidemiol. 2009;24(11):659-67
pubmed: 19504049
Arthritis Rheum. 2009 Mar 15;61(3):291-9
pubmed: 19248130
Gastroenterology. 2014 Feb;146(2):392-400.e3
pubmed: 24512909
Gut. 2004 Oct;53(10):1471-8
pubmed: 15361497
J Crohns Colitis. 2018 Nov 28;12(12):1418-1428
pubmed: 30165593
Inflamm Bowel Dis. 2019 Jun 18;25(7):1237-1247
pubmed: 30551185
BMJ Open. 2016 Oct 7;6(10):e012062
pubmed: 27855091
J Crohns Colitis. 2015 Nov;9(11):988-96
pubmed: 26129692
Ann Rheum Dis. 2015 Apr;74(4):648-54
pubmed: 24323395
J Med Econ. 2015 Jun;18(6):447-56
pubmed: 25728698
J Crohns Colitis. 2018 Apr 27;12(5):600-609
pubmed: 29718244
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Arch Med Sci. 2016 Apr 1;12(2):295-302
pubmed: 27186172
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791